您好,欢迎访问中国农业科学院 机构知识库!

A tailored nanocarrier DMON and CpGs synergistically drive the formulation of a highly immunogenic and long-acting vaccine against echinococcosis

文献类型: 外文期刊

作者: Xin, Ting 1 ; Gao, Xintao 2 ; Tao, Siyi 3 ; Zhou, Chenghao 2 ; Zhang, Zhifang 2 ; Ding, Jiabo 1 ; Ru, Jiaxi 3 ; Li, Yinue 2 ;

作者机构: 1.Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China

2.Chinese Acad Agr Sci, Biotechnol Res Inst, Natl Key Lab Agr Microbiol, Beijing 100081, Peoples R China

3.Wenzhou Med Univ, Inst Adv Res, Cixi Biomed Res Inst, Wenzhou 325035, Zhejiang, Peoples R China

关键词: Nanocarrier; DMON nanoparticle; CpG adjuvants; Vaccine; Echinococcosis; Early; robust and long-lasting immunity

期刊名称:MATERIALS TODAY BIO ( 影响因子:10.2; 五年影响因子:10.2 )

ISSN: 2590-0064

年卷期: 2025 年 32 卷

页码:

收录情况: SCI

摘要: Hydatid disease (echinococcosis) is a zoonotic parasitic disease that seriously endangers human health and livestock production. To develop a safer, more effective vaccine with an exceptionally long-lasting immune response, we employed an 'all-in-one' strategy to construct a nanovaccine against echinococcosis. In this system, a dendritic mesoporous organosilica nanoparticle (DMON), Eg95 antigen, and two types of CpG potentiators (CpG ODN and pCpG) were integrated into a single nanoplatform. Compared to the commercial Quil-Aformulated vaccine, these two nanovaccines exhibited significant advantages in inducing early, robust, and long-lasting protective immune responses, especially in terms of IgG1 antibody responses and Th1 cytokine TNF alpha secretion. Notably, the certain adjuvant combination (DMON + pCpG) formulated-vaccine Eg95N + pCpG@DMON conferred stronger adjuvanticity to the antigen than Quil-A during the late stage (42-84 days). Systematic evaluation demonstrated excellent biodegradability and biosafety of DMON and its-based vaccine. This research provides a strong foundation for upgrading vaccines against echinococcosis.

  • 相关文献
作者其他论文 更多>>